A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
about
Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapyCapecitabine in gastric cancer.Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinomaChemotherapy for gastric cancer.Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapyReport of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.Capecitabine in advanced gastric cancer.Capecitabine in the treatment of advanced gastric cancer.Accomplishments in 2007 in the management of localized gastric cancer.Capecitabine for the treatment of gastric cancer.Capecitabine for treating head and neck cancer.In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines.Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
P2860
Q33364558-EF14DD87-22AA-456B-90E0-F29E43C22FBAQ34236005-AC360A38-6891-4FFE-9812-5C0258A6A8EEQ34608222-F93CE4BF-D800-401B-B3AE-19FEC6051498Q35691049-FC46ADB4-61AB-4C41-8DC9-28425F9FAE9CQ36398226-8999110C-3A6B-49E4-AB21-1F9189E400EEQ36611129-402B999D-E6E6-4ECC-976A-F55D9D2F56B6Q36615965-FDD2806D-98FD-4B8A-AF78-8DB2AF99D2DDQ36979346-BD10A279-4F63-448B-B3E2-33446B9F1045Q37136996-4513B9A6-4F7E-48F0-BACA-4D1768D4E35CQ37149160-04171421-3628-42BC-8BBD-0EF20596A87FQ38608072-97037A66-2E06-4088-AEA2-1FAF6F51A172Q38825147-1788C6C3-1EAB-4F82-8321-3F0758AFB200Q40096386-A10C2A46-C3E6-4FE9-B8A1-924732ACD836Q41044387-87CE66E5-2845-4869-ADA0-CBE2524E1E67Q43504942-1253C672-7528-407F-8F19-24D3D0CFA96BQ43589273-B7A5AEED-00F2-4726-93D0-0A6C623C9FACQ45023409-E01255D6-D5C3-4146-9C6A-BF760A05FA97Q46326788-A146A004-BECB-4A1B-8AED-9E6C97E8AC66Q46601885-261B9972-1A9C-44D4-9C34-A4601D0D8687Q46830250-1F735E64-68F0-40D4-A55C-8A428FE0B776Q54547540-CBD6A04C-1723-4DF9-97C0-7A3E9D0A76EC
P2860
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A phase I and pharmacokinetic ...... ophago-gastric adenocarcinoma.
@ast
A phase I and pharmacokinetic ...... ophago-gastric adenocarcinoma.
@en
type
label
A phase I and pharmacokinetic ...... ophago-gastric adenocarcinoma.
@ast
A phase I and pharmacokinetic ...... ophago-gastric adenocarcinoma.
@en
prefLabel
A phase I and pharmacokinetic ...... ophago-gastric adenocarcinoma.
@ast
A phase I and pharmacokinetic ...... ophago-gastric adenocarcinoma.
@en
P2093
P356
P1433
P1476
A phase I and pharmacokinetic ...... ophago-gastric adenocarcinoma.
@en
P2093
A C McDonald
G M Fullarton
G Pentheroudakis
R Morrison
T R J Evans
P304
P356
10.1093/ANNONC/MDF243
P577
2002-09-01T00:00:00Z